CA3141271A1 - Continuous process for the preparation of anticholinergic drugs - Google Patents

Continuous process for the preparation of anticholinergic drugs Download PDF

Info

Publication number
CA3141271A1
CA3141271A1 CA3141271A CA3141271A CA3141271A1 CA 3141271 A1 CA3141271 A1 CA 3141271A1 CA 3141271 A CA3141271 A CA 3141271A CA 3141271 A CA3141271 A CA 3141271A CA 3141271 A1 CA3141271 A1 CA 3141271A1
Authority
CA
Canada
Prior art keywords
bromide
process according
anticholinergic agent
anticholinergic
continuous flow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3141271A
Other languages
English (en)
French (fr)
Inventor
Marianna KATZ
Nuno Torres Lourenco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hovione Scientia Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71120199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3141271(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA3141271A1 publication Critical patent/CA3141271A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3141271A 2019-06-17 2020-06-16 Continuous process for the preparation of anticholinergic drugs Pending CA3141271A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT115583A PT115583B (pt) 2019-06-17 2019-06-17 Processo contínuo para a preparação de medicamentos anticolinérgicos
PT115583 2019-06-17
PCT/GB2020/051448 WO2020254791A1 (en) 2019-06-17 2020-06-16 Continuous process for the preparation of anticholinergic drugs

Publications (1)

Publication Number Publication Date
CA3141271A1 true CA3141271A1 (en) 2020-12-24

Family

ID=71120199

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3141271A Pending CA3141271A1 (en) 2019-06-17 2020-06-16 Continuous process for the preparation of anticholinergic drugs

Country Status (10)

Country Link
US (1) US20220251078A1 (cg-RX-API-DMAC7.html)
EP (1) EP3982923B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022549545A (cg-RX-API-DMAC7.html)
KR (1) KR20220024433A (cg-RX-API-DMAC7.html)
CN (1) CN114206863A (cg-RX-API-DMAC7.html)
AU (1) AU2020296972B2 (cg-RX-API-DMAC7.html)
CA (1) CA3141271A1 (cg-RX-API-DMAC7.html)
IL (1) IL288972A (cg-RX-API-DMAC7.html)
PT (1) PT115583B (cg-RX-API-DMAC7.html)
WO (1) WO2020254791A1 (cg-RX-API-DMAC7.html)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
KR20080012932A (ko) 2005-05-02 2008-02-12 베링거 인겔하임 인터내셔날 게엠베하 티오트로퓸 브로마이드의 신규한 결정형
EP1879888A2 (en) 2005-05-02 2008-01-23 Boehringer Ingelheim International GmbH Crystalline forms of tiotropium bromide
RU2453547C2 (ru) 2005-12-19 2012-06-20 Сикор Инк. Новые формы тиотропия бромида и способы их получения
PT1869035E (pt) 2005-12-19 2013-01-10 Sicor Inc Novas formas de brometo de tiotrópio e processos para sua preparação
JP5333342B2 (ja) 2009-06-29 2013-11-06 株式会社デンソー 半導体装置
ES2625498T3 (es) * 2011-12-22 2017-07-19 Cerbios-Pharma S.A. Proceso continuo para la alquilación de aminas terciarias cíclicas
PT106142B (pt) 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
JP6389174B2 (ja) 2012-08-15 2018-09-12 グラクソ グループ リミテッドGlaxo Group Limited 化学的方法
CZ27764U1 (cs) 2014-08-22 2015-02-02 Zentiva, K.S. uMethanolový solvát umeclidinium bromidu
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio

Also Published As

Publication number Publication date
EP3982923C0 (en) 2024-05-15
KR20220024433A (ko) 2022-03-03
PT115583B (pt) 2022-05-02
US20220251078A1 (en) 2022-08-11
EP3982923A1 (en) 2022-04-20
PT115583A (pt) 2021-06-03
AU2020296972B2 (en) 2025-04-24
EP3982923B1 (en) 2024-05-15
CN114206863A (zh) 2022-03-18
WO2020254791A1 (en) 2020-12-24
IL288972A (en) 2022-02-01
JP2025081547A (ja) 2025-05-27
JP2022549545A (ja) 2022-11-28
AU2020296972A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
US11634377B2 (en) Fenfluramine compositions and methods of preparing the same
CN104854105B (zh) 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
US11827596B2 (en) Thyromimetics
CN102639531B (zh) 噻托溴铵的无水合物
IE55110B1 (en) Quaternary 6,11-dihydro-dibenzo(b,e)thiepin-11-n-alkyl-norscopien ethers and processes for their preparation
AU2017376363A1 (en) Class of bifunctional compounds with quaternary ammonium salt structure
CN116003387B (zh) 一种氘代吲唑丙酰胺类化合物、药物组合物和用途
CN102947300A (zh) 生物碱氨基酯衍生物及其药物组合物
EP3982923B1 (en) Continuous process for the preparation of anticholinergic drugs
CN111670191B (zh) 吡啶酮衍生物的晶型及制备方法和应用
ES2986962T3 (es) Proceso continuo para la preparación de fármacos anticolinérgicos
US20220402861A1 (en) A Crystalline form of (R)-terbutaline Hydrochloride
EP3468949B1 (en) Crystalline pharmaceutical co-crystals of glycopyrronium bromide with lactose
CN111574529A (zh) 蕈毒碱受体M3拮抗剂和β2-肾上腺素能受体激动剂桥环衍生物
KR20130099132A (ko) 4-[2-디메틸아미노-1-(1-하이드록시사이클로헥실)에틸]페닐 4-메틸벤조에이트 하이드로클로라이드의 다형체, 이의 제조 방법 및 이의 용도
US12398100B2 (en) Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
JP2022549545A5 (cg-RX-API-DMAC7.html)
HK1181769A (en) Process for the preparation of glycopyrronium chloride
HK1193086B (en) Mixed crystal agomelatine (form-viii), preparation method and use thereof and pharmaceutical composition containing same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220718

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240815

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250526

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250526

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250529

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250529

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250724

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251110

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260107

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260107

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260521

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260521

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260729